This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The COSMOS trial showed guselkumab every 8 weeks improved PsA outcomes through week 48, including in patients with inadequate responses to TNF inhibitors.
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.
Publication date: Available online 20 December 2024 Source: The American Journal of Cardiology Author(s): Ozgur Selim Ser, Deniz Mutlu, Michaella Alexandrou, Dimitrios Strepkos, Pedro E.P. Carvalho, Oleg Krestyaninov, Dimitri Khelimskii, Barkin Kultursay, Ali Karagoz, Ufuk Yildirim, Korhan Soylu, Mahmut Uluganyan, Olga Mastrodemos, Bavana V. Rangan, Sandeep Jalli, Konstantinos Voudris, M.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
A research team co-led by a physician-scientist at the University of Arizona College of MedicineTucson's Sarver Heart Center found that a subset of artificial heart patients can regenerate heart muscle, which may open the door to new ways to treat and perhaps someday cure heart failure. The results were published in the journal Circulation.
This strip shows normal sinus rhythm at a rate of 95 bpm. The isoelectric line shows the effects of the patient's breathing. Placing the limb electrodes on the limbs rather than on the chest will eliminate this artifact.
52
52
Sign up to get articles personalized to your interests!
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
This strip shows normal sinus rhythm at a rate of 95 bpm. The isoelectric line shows the effects of the patient's breathing. Placing the limb electrodes on the limbs rather than on the chest will eliminate this artifact.
Rheumatoid arthritis (RA) is associated with a higher rate of heart failure subtypes, according to a study published online Dec. 9 in Arthritis Care & Research.
Publication date: Available online 20 December 2024 Source: The American Journal of Cardiology Author(s): Peiren Zhang, Bin Luo, Peilan Zhang, Xiaoqing Yu, Xiaoyue Long, Yuxuan Du, Haozhi Tian, Liwen Wang
Publication date: Available online 21 December 2024 Source: The American Journal of Cardiology Author(s): Piera Capranzano, Paolo Calabr, Giuseppe Musumeci, Carlo Di Mario, Fabio Chirillo, Cristina Rolfo, Alberto Menozzi, Maurizio Menichelli, Diego Maffeo, Giuseppe Talanas, Marco Ferlini, Marco Contarini, Valerio Lanzilotti, Leonardo De Luca
I was sent the ECG shown in Figure-1 initially without the benefit of any history? How would you interpret this tracing? What is YOUR differential diagnosis of this tracing? Figure-1: The initial ECG in today's case. ( To improve visualization I've digitized the original ECG using PMcardio ). == The Obvious Concern: I immediately realized the reason that I was sent this tracing: ==> there is ST elevation in the anterior chest leads!
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content